- DeAngelo, Christopher;
- Tarasiewicz, Megan Burnett;
- Strother, Athena;
- Taggart, Heather;
- Gray, Caron;
- Shanahan, Meaghan;
- Glowacki, Christopher;
- Khandalavala, Jimmy;
- Talaska, Erin;
- Kinnan, Andrea;
- Coté, John Joseph;
- Edwards, Adrienne Perfilio;
- Harper-Harrison, Gina;
- Casey, Murray Joseph;
- Hirai, Traci-Lynn;
- Schultz, Sarah;
- Stines, Lynnea;
- Vora, Roma;
- Boudreau, Dominique;
- Burgart, Jennifer;
- Shama, Meredith;
- Watson, Trevor;
- Strasheim, Lisa;
- Thompson, Rachel;
- Lawlor, Rachel;
- Joyce, Kayleen;
- Magnuson, Claire M;
- Driano, Jane;
- Elger, Breanna;
- Lentino, Anne;
- Driscoll, Margaret;
- Tidwell, Elise;
- Sharma, Apoorva;
- Walker, Sarah R;
- Jones, Gretchen;
- Sharma, Poonam;
- Stessman, Holly;
- Wu, Yanyuan;
- Vadgama, Jay;
- Chase, Dana;
- Conrad, Lesley;
- Reddy, Srinivasa T;
- Farias-Eisner, Robin
Background
Endometriosis is complex, but identifying the novel biomarkers, inflammatory molecules, and genetic links holds the key to the enhanced detection, prediction and treatment of both endometriosis and endometriosis related malignant neoplasia. Here we review the literature relating to the specific molecular mechanism(s) mediating tumorigenesis arising within endometriosis.Methods
Guidance (e.g. Cochrane) and published studies were identified. The Published studies were identified through PubMed using the systematic review methods filter, and the authors' topic knowledge. These data were reviewed to identify key and relevant articles to create a comprehensive review article to explore the molecular fingerprint associated with in endometriosis-driven tumorigenesis.Results
An important focus is the link between C3aR1, PGR, ER1, SOX-17 and other relevant gene expression profiles and endometriosis-driven tumorigenesis. Further studies should also focus on the combined use of CA-125 with HE-4, and the role for OVA1/MIA as clinically relevant diagnostic biomarkers in the prediction of endometriosis-driven tumorigenesis.Conclusions
Elucidating endometriosis' molecular fingerprint is to understand the molecular mechanisms that drive the endometriosis-associated malignant phenotype. A better understanding of the predictive roles of these genes and the value of the biomarker proteins will allow for the derivation of unique molecular treatment algorithms to better serve our patients.